Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement
Coeptis Therapeutics Holdings (NASDAQ: COEP) has announced a definitive merger agreement with Z Squared Inc., a Dogecoin mining company. The merger will transform Coeptis into the largest publicly-traded, Dogecoin-focused mining company globally. Under the agreement, Z Squared will become a wholly-owned subsidiary of Coeptis in exchange for 9,000 U.S. based dogecoin mining machines.
The transaction, expected to close in Q3 2025, will involve Coeptis spinning out its biopharmaceutical operations while maintaining its technology operations. Post-merger, the company will be rebranded as Z Squared, Inc. and continue listing on Nasdaq. The combined entity will focus on mining Dogecoin (DOGE), which currently has a market cap exceeding $20B.
The new leadership team will include David Halabu as CEO and Michelle Burke as COO, while current Coeptis CEO Dave Mehalick will exit the Board upon closing. The merger is subject to shareholder approval, regulatory clearances, and continued Nasdaq listing requirements.
Coeptis Therapeutics Holdings (NASDAQ: COEP) ha annunciato un accordo definitivo di fusione con Z Squared Inc., un'azienda specializzata nel mining di Dogecoin. La fusione trasformerà Coeptis nella più grande società quotata in borsa focalizzata sul mining di Dogecoin a livello globale. Secondo l'accordo, Z Squared diventerà una controllata interamente posseduta da Coeptis in cambio di 9.000 macchine per il mining di Dogecoin basate negli Stati Uniti.
L’operazione, che si prevede si concluda nel terzo trimestre del 2025, comporterà lo scorporo delle attività biofarmaceutiche di Coeptis, mantenendo però le operazioni tecnologiche. Dopo la fusione, la società sarà rinominata Z Squared, Inc. e continuerà a essere quotata al Nasdaq. L’entità combinata si concentrerà sul mining di Dogecoin (DOGE), che attualmente ha una capitalizzazione di mercato superiore a 20 miliardi di dollari.
Il nuovo team dirigente comprenderà David Halabu come CEO e Michelle Burke come COO, mentre l’attuale CEO di Coeptis, Dave Mehalick, lascerà il Consiglio di Amministrazione al momento della chiusura. La fusione è subordinata all’approvazione degli azionisti, alle autorizzazioni regolamentari e al rispetto dei requisiti di quotazione Nasdaq.
Coeptis Therapeutics Holdings (NASDAQ: COEP) ha anunciado un acuerdo definitivo de fusión con Z Squared Inc., una empresa dedicada a la minería de Dogecoin. La fusión convertirá a Coeptis en la mayor compañía pública centrada en la minería de Dogecoin a nivel mundial. Según el acuerdo, Z Squared se convertirá en una subsidiaria de propiedad total de Coeptis a cambio de 9,000 máquinas de minería de Dogecoin ubicadas en Estados Unidos.
La transacción, que se espera cerrar en el tercer trimestre de 2025, implicará que Coeptis escinda sus operaciones biofarmacéuticas mientras mantiene sus actividades tecnológicas. Tras la fusión, la empresa se renombrará como Z Squared, Inc. y continuará cotizando en Nasdaq. La entidad combinada se enfocará en la minería de Dogecoin (DOGE), que actualmente tiene una capitalización de mercado superior a 20 mil millones de dólares.
El nuevo equipo directivo incluirá a David Halabu como CEO y a Michelle Burke como COO, mientras que el actual CEO de Coeptis, Dave Mehalick, dejará la Junta Directiva al cierre. La fusión está sujeta a la aprobación de los accionistas, a las autorizaciones regulatorias y al cumplimiento de los requisitos de cotización en Nasdaq.
Coeptis Therapeutics Holdings (NASDAQ: COEP)는 도지코인 채굴 회사인 Z Squared Inc.와 최종 합병 계약을 발표했습니다. 이번 합병으로 Coeptis는 전 세계에서 가장 큰 상장 도지코인 채굴 회사로 거듭나게 됩니다. 계약에 따라 Z Squared는 9,000대의 미국 기반 도지코인 채굴 기계를 대가로 Coeptis의 완전 자회사가 됩니다.
이번 거래는 2025년 3분기 종료를 목표로 하며, Coeptis는 바이오제약 사업부를 분사하고 기술 사업부는 유지할 예정입니다. 합병 후 회사명은 Z Squared, Inc.로 변경되며 나스닥 상장을 계속 유지합니다. 합병된 법인은 현재 시가총액이 200억 달러를 넘는 도지코인(DOGE) 채굴에 집중할 것입니다.
새로운 경영진에는 데이비드 할라부가 CEO로, 미셸 버크가 COO로 임명되며, 현 Coeptis CEO인 데이브 메할릭은 합병 완료 시 이사회에서 물러납니다. 이번 합병은 주주 승인, 규제 당국 승인 및 나스닥 상장 요건 충족을 조건으로 합니다.
Coeptis Therapeutics Holdings (NASDAQ : COEP) a annoncé un accord définitif de fusion avec Z Squared Inc., une entreprise spécialisée dans le minage de Dogecoin. Cette fusion fera de Coeptis la plus grande société cotée en bourse axée sur le minage de Dogecoin au monde. Selon l’accord, Z Squared deviendra une filiale en propriété exclusive de Coeptis en échange de 9 000 machines de minage de Dogecoin basées aux États-Unis.
La transaction, dont la clôture est prévue au troisième trimestre 2025, impliquera la scission des activités biopharmaceutiques de Coeptis tout en conservant ses opérations technologiques. Après la fusion, la société sera renommée Z Squared, Inc. et continuera d’être cotée au Nasdaq. L’entité combinée se concentrera sur le minage de Dogecoin (DOGE), qui dispose actuellement d’une capitalisation boursière dépassant les 20 milliards de dollars.
La nouvelle équipe dirigeante comprendra David Halabu en tant que CEO et Michelle Burke en tant que COO, tandis que l’actuel CEO de Coeptis, Dave Mehalick, quittera le conseil d’administration à la clôture. La fusion est soumise à l’approbation des actionnaires, aux autorisations réglementaires et au respect des exigences de cotation au Nasdaq.
Coeptis Therapeutics Holdings (NASDAQ: COEP) hat eine endgültige Fusionsvereinbarung mit Z Squared Inc., einem Dogecoin-Mining-Unternehmen, bekannt gegeben. Die Fusion wird Coeptis zum weltweit größten börsennotierten Unternehmen machen, das sich auf Dogecoin-Mining spezialisiert hat. Gemäß der Vereinbarung wird Z Squared eine hundertprozentige Tochtergesellschaft von Coeptis im Austausch für 9.000 in den USA ansässige Dogecoin-Mining-Maschinen.
Die Transaktion, die voraussichtlich im dritten Quartal 2025 abgeschlossen wird, umfasst die Ausgliederung der biopharmazeutischen Geschäfte von Coeptis bei gleichzeitiger Beibehaltung der Technologiegeschäfte. Nach der Fusion wird das Unternehmen in Z Squared, Inc. umbenannt und an der Nasdaq weiter gelistet. Das kombinierte Unternehmen wird sich auf das Mining von Dogecoin (DOGE) konzentrieren, das derzeit eine Marktkapitalisierung von über 20 Milliarden US-Dollar aufweist.
Das neue Führungsteam wird David Halabu als CEO und Michelle Burke als COO umfassen, während der derzeitige Coeptis-CEO Dave Mehalick nach Abschluss aus dem Vorstand ausscheiden wird. Die Fusion steht unter dem Vorbehalt der Zustimmung der Aktionäre, behördlicher Genehmigungen und der Einhaltung der Nasdaq-Listing-Anforderungen.
- Creation of largest publicly-traded Dogecoin mining company with exposure to $20B DOGE market
- Acquisition of 9,000 U.S. based dogecoin mining machines
- Maintained Nasdaq listing status post-merger
- Experienced leadership team with digital asset mining expertise
- Complete shift from biopharmaceutical focus to crypto mining represents significant business model risk
- Execution risk in spinning out biopharmaceutical operations
- High dependency on volatile cryptocurrency market conditions
- Regulatory uncertainties in crypto mining sector
Insights
Coeptis completely transforms from biotech to Dogecoin mining via Z Squared merger, spinning off original business with unclear financial terms.
This merger between Coeptis Therapeutics and Z Squared represents a complete business transformation that fundamentally alters the company's core operations and focus. Coeptis will essentially become a cryptocurrency mining company focused on Dogecoin, while spinning out its original biopharmaceutical operations as a separate entity.
The transaction structure involves Z Squared bringing 9,000 U.S.-based Dogecoin mining machines to Coeptis in exchange for equity. However, the announcement lacks critical financial details including valuation metrics, cash considerations, or the post-merger ownership structure between current Coeptis shareholders and Z Squared stakeholders.
This represents a classic "reverse merger" strategy allowing Z Squared to gain public listing on Nasdaq without undergoing a traditional IPO process. For existing Coeptis investors, this constitutes a complete pivot from their original investment thesis in biopharmaceuticals to cryptocurrency mining – industries with vastly different risk profiles.
The leadership will undergo a complete transition, with Z Squared executives David Halabu (CEO) and Michelle Burke (COO) taking control, while current Coeptis CEO Dave Mehalick exits the board upon closing. The transaction is expected to complete in Q3 2025, subject to shareholder approval and regulatory clearances.
For current Coeptis shareholders, the value proposition becomes bifurcated – they maintain exposure to the original biopharmaceutical operations through the spin-off, while also gaining exposure to cryptocurrency mining. Without detailed financial terms, the relative value allocation between these components remains unclear.
Z Squared merger positions Coeptis as US-leading public Dogecoin mining company, though operational economics and profitability details remain undisclosed.
This merger transforms Coeptis into what the companies claim will be "the largest publicly-traded company in the United States primarily focused on DOGE mining." The business model centers on deploying 9,000 specialized mining machines to earn Dogecoin rewards through the blockchain's proof-of-work (PoW) mechanism.
Dogecoin, with its stated
The incoming leadership brings relevant experience to the cryptocurrency operation. Michelle Burke previously served as CEO at "Minting Dome Inc." described as a "pre-eminent digital asset mining company," while David Halabu brings alternative investment expertise as former Managing Partner of Group 10 Capital Management.
However, the announcement lacks critical operational details that would help assess the mining operation's potential. There's no mention of the mining facilities' locations, electricity costs, expected hash rates, or projected mining yields – all factors that significantly impact mining profitability alongside cryptocurrency prices and network difficulty.
This merger represents a calculated bet on Dogecoin's continued relevance in the cryptocurrency ecosystem. For investors, it provides a pure-play public vehicle for Dogecoin mining exposure, though with the inherent volatility and regulatory uncertainties that characterize the cryptocurrency mining sector.
Aim to create the largest publicly-traded, Dogecoin-focused mining company in the world Coeptis to spin out biopharmaceutical operations
WEXFORD, Pa., April 25, 2025 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq; COEP) (“Coeptis” or the “Company”), a biopharmaceutical and technology company focused on developing innovative cell therapy platforms for cancer, autoimmune and infectious diseases, and Z Squared Inc. (“Z Squared”), a Dogecoin mining company, today announced they have entered into a definitive merger agreement for a business combination that will result in Z Squared becoming a wholly-owned subsidiary of Coeptis. Under the terms of the merger agreement, a wholly-owned subsidiary of Coeptis will merge with and into Z Squared and the holders of the outstanding Z Squared shares will receive equity in Coeptis in exchange for 9,000 U.S. based dogecoin mining machines at closing. The Boards of Directors of both Coeptis and Z Squared have approved the proposed merger, which is subject to customary closing conditions, including receipt of all regulatory approvals, continued Nasdaq listing and the approval of the proposed merger by Coeptis’ and Z Squared’s shareholders. In connection with the merger, Coeptis intends to spin out its biopharmaceutical operations, and continue to operate those operations separate from Coeptis after the merger. The technology operations will remain in the Company after the merger. Assuming all conditions to closing are satisfied, the close of the transaction is anticipated to occur in the third quarter of 2025. It is anticipated that Coeptis will be rebranded and operate as Z Squared, Inc., and is expected to list on the Nasdaq Capital Market.
The combined Company will focus on advancing Z Squared’s digital asset mining expertise, which focuses primarily on generating Dogecoin (“DOGE”), along with other digital assets. DOGE has a market cap of over
The surviving entity will be led by Z Squared executives, David Halabu as Chief Executive Officer and Michelle Burke as Chief Operating Officer. Current Coeptis President and Chief Executive Officer, Dave Mehalick, will exit from the Board of Directors upon closing. Prior to serving as Chief Executive Officer of Z Squared, David Halabu was the founder and Managing Partner of multi-vertical alternative investment firm, Group 10 Capital Management.
Michelle Burke was most recently the Chief Executive Officer at the pre-eminent digital asset mining company, Minting Dome Inc.
"We are excited to take this step towards our goal of creating the largest publicly-traded company in the United States primarily focused on DOGE mining," said David Halabu. "We’re proud of our strategy to bring retail and institutional audiences alike in the public markets a focused exposure to a DOGE asset that currently has over
"We are excited to bring this opportunity to our shareholders to become involved in the Dogecoin market space, while at the same time being able to remain involved in our biopharmaceutical operations as a result of the contemplated spin out of those operations at closing," said Dave Mehalick. "I’ve been deeply engaged in the evolution of blockchain infrastructure and am aligned with the direction the new leadership intends to take the Company."
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., SNAP Biosciences, Inc., and Coeptis Technologies (collectively "Coeptis"), is a biopharmaceutical and technology company. The biopharmaceutical divisions focus on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts.
Coeptis’ therapeutic portfolio is underscored by assets licensed from Deverra Therapeutics, which include an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Coeptis is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and distinguished medical researchers at the Karolinska Institute.
Building on its core competencies, Coeptis has recently established a Technology Division, which focuses on enhancing operational capabilities through advanced technologies. This division features AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group, designed to optimize business processes and improve overall efficiency.
Headquartered in Wexford, PA, Coeptis is dedicated to advancing its mission within the regulatory framework set forth by the Food and Drug Administration, ensuring that all activities align with the highest standards of compliance and patient care. For more information on Coeptis and its lines of business, visit https://coeptistx.com About Z Squared Inc.
Z Squared Inc. is a digital asset mining company, focused primarily on the generation of Dogecoin (DOGE), along with other digital assets such as Litecoin and other altcoins. Z Squared aims to unlock gainful investor mining exposure to DOGE, its
Additional Information and Where to Find It
In connection with the merger agreement and the proposed business combination, Coeptis intends to file with the SEC a Registration Statement, which will include a preliminary proxy statement/prospectus and a proxy statement/prospectus. Coeptis’ stockholders and other interested persons are advised to read, when available, the preliminary proxy statement/prospectus and the amendments thereto and the definitive proxy statement/prospectus and documents incorporated by reference therein filed in connection with the business combination, as these materials will contain important information about Coeptis, Z Squared, the merger agreement, the business combination and the spin out. When available, the definitive proxy statement/prospectus and other relevant materials for the business combination will be mailed to stockholders of Coeptis and Z Squared as of a record date to be established for voting on the business combination and spin out. Stockholders of Coeptis and Z Squared will also be able to obtain copies of the Registration Statement, the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus and other documents filed with the SEC that will be incorporated by reference therein, without charge, once available, at the SEC’s web site at www.sec.gov.
Participants in the Solicitation
Coeptis, Z Squared and their respective directors, executive officers, other members of management and employees may be deemed participants in the solicitation of proxies from Coeptis’ and Z Squared’s stockholders with respect to the proposed business combination and spin out. Investors and securityholders may obtain more detailed information regarding the names and interests in the business combination of the directors and officers of each of Coeptis and Z Squared in such companies’ respective filings with the SEC, including the Registration Statement.
No Offer or Solicitation
This press release shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed business combination or spin out. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in connection therewith contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. These statements are subject to significant uncertainties and risks including, but not limited, to those risks contained in reports filed by Coeptis with the Securities and Exchange Commission (the "SEC"). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings made or to be made with the SEC, which are available for review at www.sec.gov. We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations, or rules.
Contacts
IR@coeptistx.com
FAQ
What is the exchange ratio for the COEP and Z Squared merger?
When is the COEP merger with Z Squared expected to close?
What will happen to Coeptis' biopharmaceutical operations after the merger?
Who will lead the combined company after the COEP-Z Squared merger?
What is the main business focus of the merged COEP-Z Squared company?
